Nothing Special   »   [go: up one dir, main page]

BR112013029416A2 - derivados de indol substituídos para o tratamento de distúrbios imunológicos - Google Patents

derivados de indol substituídos para o tratamento de distúrbios imunológicos

Info

Publication number
BR112013029416A2
BR112013029416A2 BR112013029416A BR112013029416A BR112013029416A2 BR 112013029416 A2 BR112013029416 A2 BR 112013029416A2 BR 112013029416 A BR112013029416 A BR 112013029416A BR 112013029416 A BR112013029416 A BR 112013029416A BR 112013029416 A2 BR112013029416 A2 BR 112013029416A2
Authority
BR
Brazil
Prior art keywords
treatment
indole derivatives
substituted indole
immune disorders
substituted
Prior art date
Application number
BR112013029416A
Other languages
English (en)
Inventor
Kammertoens Karen
Van Eis Maurice
Graham Cooke Nigel
Ramos Rita
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013029416A2 publication Critical patent/BR112013029416A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499Spiro-condensed pyrazines or piperazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)

Abstract

resumo patente de invenção: "derivados de indol substituídos para o tratamento de distúrbios imunológicos". a presente invenção refere-se a derivados de indol substituídos, a processos para a sua produção, sua utilização como produtos farmacêuticos e a composições farmacêuticas que os compreendem. 19764779v1
BR112013029416A 2011-05-17 2012-05-16 derivados de indol substituídos para o tratamento de distúrbios imunológicos BR112013029416A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486808P 2011-05-17 2011-05-17
PCT/IB2012/052473 WO2012156936A1 (en) 2011-05-17 2012-05-16 Substituted indole derivatives for the treatment of immunological disorders

Publications (1)

Publication Number Publication Date
BR112013029416A2 true BR112013029416A2 (pt) 2017-01-31

Family

ID=46210333

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013029416A BR112013029416A2 (pt) 2011-05-17 2012-05-16 derivados de indol substituídos para o tratamento de distúrbios imunológicos

Country Status (15)

Country Link
US (2) US8703782B2 (pt)
EP (1) EP2709998B1 (pt)
JP (1) JP6043344B2 (pt)
KR (1) KR20140023354A (pt)
CN (1) CN103534250B (pt)
AR (1) AR088414A1 (pt)
AU (1) AU2012257345B2 (pt)
BR (1) BR112013029416A2 (pt)
CA (1) CA2835169C (pt)
EA (1) EA023238B1 (pt)
ES (1) ES2565200T3 (pt)
MX (1) MX2013013436A (pt)
TW (1) TW201249858A (pt)
UY (1) UY34072A (pt)
WO (1) WO2012156936A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol
WO2014072911A1 (en) * 2012-11-07 2014-05-15 Novartis Ag Substituted indole derivatives
EP4005573A1 (en) * 2013-08-14 2022-06-01 Novartis AG Combination therapy for the treatment of cancer
WO2015039187A1 (en) 2013-09-18 2015-03-26 University Of Canberra Stem cell modulation ii
CN107106517A (zh) 2014-08-25 2017-08-29 堪培拉大学 用于调节癌干细胞的组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925860A (en) 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
YU25202A (sh) * 1999-10-12 2004-12-31 F.Hoffmann-La Roche Ag. Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
PT1337527E (pt) * 2000-11-07 2009-12-10 Novartis Ag Derivados de indolilmaleimida como inibidores da proteína quinase c
PL205940B1 (pl) 2001-12-21 2010-06-30 Mgi Gp Sposób wytwarzania rozpuszczalnych w wodzie pochodnych fosfonooksymetylowych alkoholu i fenolu
ATE430571T1 (de) 2001-12-28 2009-05-15 Eisai Corp North America Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol- verbindungen
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
PL373850A1 (en) 2002-04-08 2005-09-19 Guilford Pharmaceuticals, Inc. Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
AU2003223104A1 (en) 2003-03-19 2004-10-11 Suven Life Sciences Limited A process for the preparation of indolymaleimides
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
WO2007008514A2 (en) 2005-07-07 2007-01-18 Georgetown University Inhibitors of glycogen synthase kinase 3
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
GB0605691D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
US8163902B2 (en) 2006-11-21 2012-04-24 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20150018301A1 (en) 2009-11-06 2015-01-15 The Johns Hopkins University LRRK-2-Mediated Neuronal Toxicity
CN101812097B (zh) 2010-04-17 2012-04-25 中国海洋大学 吲哚咔唑和双吲哚马来酰亚胺生物碱及其制备方法和应用
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol

Also Published As

Publication number Publication date
ES2565200T3 (es) 2016-04-01
EP2709998B1 (en) 2016-01-06
EA201391710A1 (ru) 2014-03-31
AU2012257345B2 (en) 2016-03-24
KR20140023354A (ko) 2014-02-26
US20130157980A1 (en) 2013-06-20
JP6043344B2 (ja) 2016-12-14
EA023238B1 (ru) 2016-05-31
US20140179634A1 (en) 2014-06-26
CN103534250A (zh) 2014-01-22
UY34072A (es) 2013-01-03
AR088414A1 (es) 2014-06-11
MX2013013436A (es) 2013-12-06
US9029396B2 (en) 2015-05-12
EP2709998A1 (en) 2014-03-26
TW201249858A (en) 2012-12-16
WO2012156936A1 (en) 2012-11-22
CN103534250B (zh) 2016-05-11
CA2835169A1 (en) 2012-11-22
CA2835169C (en) 2019-05-14
JP2014518870A (ja) 2014-08-07
US8703782B2 (en) 2014-04-22

Similar Documents

Publication Publication Date Title
UA114476C2 (uk) Хіназолінові похідні для лікування вірусних інфекцій та подальших захворювань
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CU20140082A7 (es) Pirimidinas y triazinas fusionadas sustituidas y sus uso
EA201490540A1 (ru) Соединения и композиции в качестве ингибиторов с-kit киназы
PH12016500094A1 (en) Autotaxin inhibitors
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
EA201490420A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
EA201690521A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
PH12016500814B1 (en) Heteroaryl butanoic acid derivatives
EA201500112A1 (ru) 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
UA109260C2 (uk) Хромонові похідні, спосіб їх одержання та їх терапевтичні застосування
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
EA201590562A1 (ru) Бензамиды
BR112013029416A2 (pt) derivados de indol substituídos para o tratamento de distúrbios imunológicos
EA201400444A1 (ru) Производные 2-оксопиперидинила
UA117780C2 (uk) Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
BR112015015373A2 (pt) métodos de integração da produção de aluminoxano na produçâo de catalisador
BR112014010719A2 (pt) moduladores não competitivos de receptor nicotínico
IN2015DN02660A (pt)
UA113887C2 (xx) 5-амінотетрагідрохінолін-2-карбонові кислоти і їх застосування

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]